Recruitment status changed
Before: Recruiting. After: Terminated.
Among the trials TrialRedline tracks, 84 changed their ClinicalTrials.gov record in July 2026: 1 status change to terminated, withdrawn or suspended, 14 primary outcome text edits, 23 completion dates moved later, 2 completion dates moved earlier, 24 enrollment changes, 51 other status changes. Each entry shows the previous and updated value and links to the registry's own version comparison.
1 in July 2026. Recruitment status changed to Terminated, Withdrawn or Suspended. Terminated first, then newest.
Before: Recruiting. After: Terminated.
14 in July 2026. The text of the main study measures changed. Edits to capitalization, punctuation or spacing alone are left out. Newest first.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Cohort 1 and 2: Objective Response Rate Measure: Cohort 3: Adverse Events Measure: Cohort 4: Efficacy and Adverse Events Measure: Cohort 5: Efficacy and Adverse Events. After: Measure: Cohort 1 and 2: Objective Response Rate Measure: Cohort 3: Adverse Events Measure: Cohort 4: Adverse Events Measure: Cohort 4: Efficacy/Objective Response Rate Measure: Cohort 5: Adverse Events Measure: Cohort 5: Efficacy/Objective Response Rate.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline in the average number of heavy drinking days per week, with a heavy drinking day defined as 5 or more drinks in the day for men and 4 or more drinks in the day for women, using the TLFB method. After: Measure: Change from baseline in the average number of heavy drinking days per week.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Pain at Visit 4.. After: Measure: Absence of Anterior Chamber Cells at Visit 6. Measure: Absence of Ocular Pain at Visit 4..
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: ATEV Primary Patency - Extremity Group (Non-iatrogenic) Measure: Rate of ATEV Infection - Extremity Group (Non-iatrogenic) Measure: Number of Participants With Adverse Events for Each Severity Grade - Extremity Group (Non-iatrogenic). After: Measure: Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the All HAV Group Measure: Primary Patency Rate of the Human Acellular Vessel (HAV) at Day 30 in the Extremity Community-Acquired Trauma Subgroup.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Frequency, Severity, and Relationship to Investigational Drug of Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs). After: Measure: Incidence of Treatment Emergent Adverse Events (TEAEs).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Part 2: Area under the curve (AUC) From Week 0 to Week 12 [AUC(0-W12)] of Ublituximab. After: Measure: Part 2: Area under the curve (AUC) at Steady State [AUCss] of Ublituximab.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Frequency and Incidence of Treatment-emergent Adverse Events. After: Measure: Number of Participants With Adverse Events.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Time to resolution of RSV Lower Respiratory Tract Disease (LRTD) symptoms. After: Measure: Time to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms Measure: Time to Complete Resolution of LRTD Symptoms for the mITT Population Measure: Time to Complete Resolution of LRTD Symptoms for the HR3 Population.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 28. After: Measure: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Day 28.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Infection Rate as Measured by the Proportion of Subjects With an Surgical Site Infection (SSI) Event in the Population of Subjects With Target Incision Length >20 cm. After: Measure: Infection Rate as Measured by the Percentage of Subjects With SSI Event in the Target Incision Within 30 Days Post Index Surgery or Re-interventions or Death [for Any Reason] in the Population of Subjects With Target Incision Length >20 cm.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Incidence of adverse events (AEs) to evaluate the safety of ADX-097. After: Measure: Number of participants reporting treatment emergent adverse events (TEAEs).
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: A reduction from baseline by 25% and/or > 100 points in the Crohn's Disease Activity Index (CDAI) scores at both Week 4 (Day 29) and at Week 6 (Day 43).. After: Measure: Percentage of Subjects With Clinical Response Based on Crohn's Disease Activity Index (CDAI) at Both Week 4 and Week 6.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: To assess the effect of tonlamarsen on plasma angiotensinogen (AGT) levels Measure: To assess the systolic blood pressure-lowering effect of tonlamarsen. After: Measure: Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions Measure: Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levels.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Safety and tolerability of intravenous ANX005 administered for up to 22 weeks in subjects with, or at risk for, manifest Huntington's Disease Measure: Pharmacokinetics (PK) of ANX005 Measure: Pharmacodynamics (PD) effects of ANX005. After: Measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Measure: Actual Dose of ANX005 Administered on Day 1 Measure: Actual Dose of ANX005 Administered on Week 22 Measure: Area Under the Concentration Versus Time Curve From Time 0 to t (AUC0-t) of ANX005 at Day 1 Measure: CSF Free Complement Component 1q (C1q) at Day 1 Measure: Blood Free C1q at Day 1 Measure: Change From Baseline in Complement C4a in CSF at Week 24 Measure: Change From Baseline in Complement C4a in CSF at Week 36 Measure: Change From Baseline in CSF NfL Level at Week 24 Measure: Change From Baseline in CSF NfL Level at Week 36 Measure: Change From Baseline in Blood NfL Level at Week 24 Measure: Change From Baseline in Blood NfL Level at Week 36.
23 in July 2026. Primary completion date moved later while its type (estimated or actual) stayed the same. Largest move first.
Before: 1 Jan 2029. After: 30 Sep 2030.
Before: 1 Dec 2026. After: 1 Dec 2027.
Before: 28 Jan 2022. After: 29 Aug 2022.
Before: 30 Jun 2027. After: 30 Dec 2027.
Before: 30 Jun 2023. After: 19 Sep 2023.
Before: 9 Oct 2026. After: 24 Nov 2026.
Before: 16 Jun 2026. After: 30 Jun 2026.
Before: Jun 2026. After: Dec 2027.
Before: Jul 2025. After: 15 Dec 2026.
Before: Sep 2026. After: Apr 2027.
Before: Dec 2025. After: Dec 2026.
Before: Jun 2026. After: Sep 2026.
Before: Dec 2026. After: Jun 2027.
Before: Sep 2026. After: Jun 2027.
Before: Jun 2026. After: Jun 2027.
Before: Jun 2026. After: Aug 2026.
Before: Aug 2026. After: Sep 2026.
Before: Jun 2026. After: Jun 2027.
Before: Apr 2026. After: Jul 2026.
Before: Jun 2026. After: Dec 2026.
Before: Jun 2026. After: Feb 2028.
Before: Nov 2025. After: Sep 2026.
Before: Jun 2026. After: Nov 2026.
2 in July 2026. Primary completion date moved earlier while its type stayed the same. Largest move first.
Before: 31 Jul 2027. After: 30 May 2027.
Before: Apr 2028. After: Oct 2027.
24 in July 2026. The participant count changed. Planned and actual counts are shown as recorded. Newest first.
Before: 100 participants (planned). After: 108 participants (actual).
Before: 100 participants (planned). After: 79 participants (planned).
Before: 316 participants (actual). After: 330 participants (planned).
Before: 51 participants (actual). After: 72 participants (actual).
Before: 56 participants (planned). After: 74 participants (planned).
Before: 150 participants (planned). After: 225 participants (planned).
Before: 560 participants (planned). After: 121 participants (actual).
Before: 12 participants (planned). After: 9 participants (actual).
Before: 25 participants (planned). After: 27 participants (actual).
Before: 276 participants (planned). After: 290 participants (actual).
Before: 60 participants (planned). After: 62 participants (actual).
Before: 186 participants (actual). After: 187 participants (actual).
Before: 30 participants (planned). After: 28 participants (actual).
Before: 80 participants (planned). After: 70 participants (actual).
Before: 0 participants (actual). After: 30 participants (planned).
Before: 700 participants (planned). After: 722 participants (actual).
Before: 15 participants (planned). After: 17 participants (actual).
Before: 180 participants (planned). After: 191 participants (planned).
Before: 992 participants (actual). After: 979 participants (actual).
Before: 332 participants (planned). After: 430 participants (actual).
Before: 332 participants (planned). After: 422 participants (actual).
Before: 10 participants (planned). After: 20 participants (actual).
Before: 100 participants (planned). After: 140 participants (planned).
Before: 160 participants (planned). After: 182 participants (actual).
51 in July 2026. Any other change of recruitment status, such as recruiting to completed. Newest first.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Active not recruiting. After: Completed.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Completed.
Before: Active not recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Completed.
Before: Recruiting. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Enrolling by invitation. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Not yet recruiting. After: Recruiting.
Before: Recruiting. After: Active not recruiting.
Before: Enrolling by invitation. After: Active not recruiting.
Before: Recruiting. After: Active not recruiting.
Showing 25 of 51. Browse all tracked trials to open the rest.
TrialRedline, “Clinical trial registry changes: July 2026”. https://trialredline.com/reports/2026-07
Based on public ClinicalTrials.gov record history. How we collect and check the data